Table 4.

Cost–utility when age limit is raised to 60 and 70 years (representing an annual cohort from England)

Scenario	Base case (CRC under 50 years)	CRC under 60 years	CRC under 70 years
Incremental costs of Strategy 5 vs Strategy 1(1) [£ Thousands]
Diagnosis	586.0	1590.5	4132.2
CRC prevention	817.1	1630.3	2990.5
CRC treatment	−725.2	−1450.7	−2604.6
EC prevention	374.5	772.5	1430.4
EC treatment	−68.0	−139.2	−247.9
Total	984.5	2403.4	5700.5
Incremental QALYs Strategy 5 vs Strategy 1(1)
Short-term	−4.6	−9.5	−18.1
Long-term	183.9	322.4	574.4
Total	179.3	312.9	556.3
Cost–utility of Strategy 5 vs Strategy 1(1)
ICER [cost per QALY gained]	£5491	£7681	£10247
INHB at WTP £20,000/QALY [QALYs]	130.1	192.8	271.3

Abbreviations: EC endometrial cancer, WTP willingness-to-pay.